# NCT05533463 (NCT05533463)

> Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

No report yet. It can be ordered.

- Drugs tested: HRS-4642
- Indication: advanced KRAS G12D-mutant solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05533463
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Conditions: Advanced KRAS G12D Mutant Solid Tumors
- Interventions: HRS-4642
- Enrollment: 102
- Primary outcome: Safety endpoints: adverse events(AEs), serious adverse events（SAEs）.
- Primary outcome: Dose Limited Toxicity(DLT)
- Primary outcome: Maximum tolerated dose (MTD)
- Primary outcome: RP2D

## Indexed commentary on NCT05533463 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct05533463